Abstract
The antibody-drug conjugate (ADC) loncastuximab tesirine (loncastuximab tesirine-lpyl, Zynlonta (R)), is a useful option for third-line and subsequent......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
